miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

BACKGROUND: Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been extensively studied, however, not much is known about the involvement of microR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: van Jaarsveld, Marijn T. M., van Kuijk, Patricia F., Boersma, Antonius W. M., Helleman, Jozien, van IJcken, Wilfred F., Mathijssen, Ron H. J., Pothof, Joris, Berns, Els M. J. J., Verweij, Jaap, Wiemer, Erik A. C.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4650519/
https://ncbi.nlm.nih.gov/pubmed/26576679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0464-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados